News
-
AstraZeneca announced the that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the company’s marketing application for a reformulated Trixeo (Breztri) Aerosphere budesonide / glycopyrronium / formoterol fumarate that uses Honeywell’s Solstice Air HFO-1234ze as… Read more . . .
-
Aptar CSP Technologies has announced an expansion of its cGMP manufacturing capacity for clinical packaging of dry powder inhalation capsules using the company’s Activ-Blister technology. Aptar CSP cited growing demand for the technology for both… Read more . . .
-
3P innovation has announced that it is now offering new filling technology in its custom-built DPI filling systems that is based on equipment originally patented by GSK for high-speed filling of Diskus dry powder inhalers.… Read more . . .
-
LTR Pharma announced a development agreement with Strategic Drug Solutions, Inc. for development of a nasal spray for the treatment of esophageal motility disorders (difficulty in swallowing). The Australian company says that the product will… Read more . . .
-
Intertek has announced a 6,000 sq ft expansion of its facility in Melbourn, UK to add laboratory space for characterization of large molecules for inhalation. In 2019, the company acquired a facility that doubled its… Read more . . .
-
Vaccine developer Ethris, which recently received $5 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for development of spray-dried RNA vaccines for nasal delivery, has announced that EU4Health has awarded the company… Read more . . .
-
According to AstraZeneca, the Phase 3 KALOS and LOGOS trials comparing Breztri (Trixeo) Aerosphere budesonide / glycopyrronium / formoterol fumarate MDI to inhaled ICS/LABA in patients with uncontrolled asthma both met their primary endpoints. Breztri… Read more . . .
-
Ritedose Pharmaceuticals has announced that the FDA approved the transfer of an ANDA for formoterol fumarate inhalation solution to Ritedose in April 2025. The company says that it expects to start shipping formoterol fumarate inhalation solution… Read more . . .
-
According to Satsuma Pharmaceuticals, the FDA has approved the company’s NDA for Atzumi dihydroergotamine nasal powder (STS101) for the treatment of migraine in adults. Although the Phase 3 SUMMIT trial of STS101 failed to meet its… Read more . . .
-
Inhalation CDMO Bespak announced that it has completed an independently verified life cycle assessment to evaluate environmental impacts associated with materials and manufacturing of its BK357 metered dose inhaler valve. The company said that the assessment… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.